Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | KDM6B | O15054 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9011917 | 0.89 | — | — | |
| SCHEMBL9012324 | 0.89 | PDE3B (0.31) | — | |
| SCHEMBL9011902 | 0.86 | AR (0.36) | IDO1TAAR1ADRA2AADRA2CADRA1D | |
| SCHEMBL9011918 | 0.85 | ADRA2A (0.32) | TAAR1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL9011960 | 0.85 | ITK (0.30) | — | |
| SCHEMBL9012300 | 0.84 | KDM4E (0.32) | — | |
| SCHEMBL9012162 | 0.83 | TAAR1 (0.35) | TAAR1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL6483558 | 0.83 | ADRA2A (0.31) | TAAR1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL9013435 | 0.82 | TAAR1 (0.34) | TAAR1 | |
| SCHEMBL9011963 | 0.82 | TAAR1 (0.39) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5523317-A | ADMINISTERING IMIDAZOLE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 1996-06-04 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0354788-B1 | Novel imidazole derivatives | NIPPON CHEMIPHAR CO (JP) | 1995-09-13 | — | — | EP | disclosed |
| EP-0633026-A1 | Use of imidazole derivative for antihypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0584588-A1 | Anti-ulcer composition containing imidazole derivative | NIPPON CHEMIPHAR CO., LTD. (JP) | 1994-03-02 | — | — | EP | disclosed |
| US-5180836-A | Antiulcer agents | NIPPON CHEMIPHAR CO., LTD. (JP) | 1993-01-19 | — | — | US | disclosed |
| US-5082943-A | Antiulcer | NIPPON CHEMIPHAR CO., LTD. (JP) | 1992-01-21 | — | — | US | disclosed |
| EP-0354788-A1 | Novel imidazole derivatives | NIPPON CHEMIPHAR CO., LTD. (JP) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | IDO1 1935/4885CCNT1 2918/4885CCNE1 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.